Scarica l'app Stockscreener
45.47
0.78%
0.35
Dopo l'orario di chiusura:
45.47
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$45.12
Aprire:
$45
Volume 24 ore:
2.17M
Relative Volume:
0.57
Capitalizzazione di mercato:
$19.48B
Reddito:
$2.35B
Utile/perdita netta:
$1.30B
Rapporto P/E:
26.00
EPS:
1.7487
Flusso di cassa netto:
$1.05B
1 W Prestazione:
+0.62%
1M Prestazione:
+12.55%
6M Prestazione:
+25.19%
1 anno Prestazione:
+36.06%
Intervallo 1D:
$44.97
$45.68
Intervallo di 1 settimana:
$44.67
$46.14
Portata 52W:
$29.66
$46.14
Royalty Pharma Plc Stock (RPRX) Company Profile
Nome
Royalty Pharma Plc
Settore
Industria
Telefono
(212) 883-0200
Indirizzo
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
45.47 | 19.33B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.01 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.04 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
826.25 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.35 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
370.67 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | UBS | Neutral → Buy |
| 2025-09-30 | Iniziato | Goldman | Buy |
| 2025-05-16 | Iniziato | Morgan Stanley | Overweight |
| 2024-06-03 | Downgrade | UBS | Buy → Neutral |
| 2022-06-14 | Ripresa | UBS | Buy |
| 2022-05-13 | Iniziato | Scotiabank | Sector Outperform |
| 2022-04-27 | Iniziato | Goldman | Buy |
| 2022-04-14 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2021-10-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-07-30 | Iniziato | Tigress Financial | Buy |
| 2020-11-09 | Aggiornamento | UBS | Neutral → Buy |
| 2020-07-14 | Iniziato | Evercore ISI | In-line |
| 2020-07-13 | Iniziato | BofA Securities | Buy |
| 2020-07-13 | Iniziato | Citigroup | Neutral |
| 2020-07-13 | Iniziato | Cowen | Outperform |
| 2020-07-13 | Iniziato | Goldman | Neutral |
| 2020-07-13 | Iniziato | JP Morgan | Neutral |
| 2020-07-13 | Iniziato | Morgan Stanley | Equal-Weight |
| 2020-07-13 | Iniziato | SunTrust | Buy |
| 2020-07-13 | Iniziato | UBS | Neutral |
Mostra tutto
Royalty Pharma Plc Borsa (RPRX) Ultime notizie
Tredje AP fonden Sells 39,546 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Support Test: Is Royalty Pharma plc benefiting from innovation trends2025 Stock Rankings & Risk Managed Trade Strategies - baoquankhu1.vn
Can Royalty Pharma plc stock deliver strong Q4 earningsNew Guidance & Consistent Growth Stock Picks - mfd.ru
PTC’s Sephience Launch Appears Off To A Strong Start - Citeline News & Insights
Will Royalty Pharma plc outperform the market in YEARDay Trade & Safe Capital Allocation Plans - mfd.ru
CenterBook Partners LP Reduces Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma PLC $RPRX Shares Bought by Aberdeen Group plc - MarketBeat
MACD Signal: Can Royalty Pharma plc deliver consistent dividends2025 Market Trends & Weekly Market Pulse Alerts - baoquankhu1.vn
5 Insightful Analyst Questions From Royalty Pharma's Q4 Earnings Call - Finviz
Heartland Advisors Inc. Purchases New Shares in Royalty Pharma PLC $RPRX - MarketBeat
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call - Barchart.com
Stronger 2026 Guidance, Buybacks, and Manager Shift Might Change The Case For Investing In Royalty Pharma (RPRX) - simplywall.st
Royalty Pharma (NASDAQ:RPRX) Sets New 1-Year HighWhat's Next? - MarketBeat
Royalty Pharma : Q4 2025 Financial Results Call Transcript - marketscreener.com
Illinois Municipal Retirement Fund Sells 22,256 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma to buy royalty interest in Amgen’s Imdelltra for up to $950M - MSN
Block Trades: Is Royalty Pharma plc likely to announce a buyback2025 EndofYear Setup & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Envestnet Asset Management Inc. Purchases 339,839 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma: 2025 Financial Performance And Strategic Outlook - Seeking Alpha
Royalty Pharma (RPRX): Unveiling A 12.86% Upside Potential With Strong Buy Ratings - DirectorsTalk Interviews
(RPRX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Quarterly Recap: Is Royalty Pharma plc stock undervalued right now2025 Stock Rankings & Smart Allocation Stock Tips - baoquankhu1.vn
Royalty Pharma plc (NASDAQ:RPRX) Passed Our Checks, And It's About To Pay A US$0.235 Dividend - Yahoo Finance
Activity Recap: Does IONS stock benefit from AI growthJuly 2025 Update & High Conviction Trade Alerts - baoquankhu1.vn
Wall Street Zen Downgrades Royalty Pharma (NASDAQ:RPRX) to Buy - MarketBeat
Royalty Pharma targets 3%–8% royalty receipts growth in 2026 while advancing $4.7B in transactions - MSN
Royalty Pharma Earnings Call Balances Strength And Risk - TipRanks
Royalty Pharma (RPRX) Margin Reset To 32.6% Tests Bullish Profitability Narratives - Sahm
New South Capital Management Inc. Purchases 31,694 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Cookson Peirce & Co. Inc. Buys 338,623 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Will Royalty Pharma plc stock see insider buyingMarket Weekly Review & Growth Focused Stock Reports - mfd.ru
Risks Report: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Intraday High Probability Setup Alerts - baoquankhu1.vn
Arrowhead Stock Has Skyrocketed 290% in One Year, and One Fund Trimmed Its Holdings by $4 Million - AOL.com
Royalty Pharma: Strong Execution And Visible Pipeline Support Our Buy View (NASDAQ:RPRX) - Seeking Alpha
S P Trends: Is Royalty Pharma plc likely to announce a buybackWeekly Stock Recap & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Royalty Pharma price target raised to $51 from $45 at Goldman Sachs - TipRanks
Royalty Pharma plc (NASDAQ:RPRX) Q4 2025 Earnings Call Transcript - Insider Monkey
BofA Securities reiterates Buy rating on Royalty Pharma stock with $54 target - Investing.com Nigeria
BofA Securities Reiterates Buy Rating on Royalty Pharma (RPRX) - StreetInsider
Royalty Pharma stock hits 52-week high at 44.94 USD By Investing.com - Investing.com South Africa
Royalty Pharma's Disciplined Capital Allocation Approach and Appealing Market Growth Bolster Outlook - Morningstar
Royalty Pharma PLC (RPRX): A Strategic SWOT Insight - GuruFocus
Royalty Pharma Q4 2025 slides: double-digit growth amid synthetic royalty expansion - Investing.com Nigeria
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
Royalty Pharma earnings beat by $0.22, revenue fell short of estimates - Investing.com UK
Royalty Pharma plc (RPRX) Reports Q4 results - StreetInsider
Earnings Call Summary | Royalty Pharma(RPRX.US) Q4 2025 Earnings Conference - 富途牛牛
Royalty Pharma earnings beat by $0.22, revenue topped estimates - Investing.com Nigeria
Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.235 - simplywall.st
Royalty Pharma (RPRX) Strengthens Pipeline With New Oncology Royalty Purchase - MSN
Assessing Royalty Pharma (RPRX) Valuation After Recent Share Price Momentum - Yahoo Finance
Royalty Pharma Plc Azioni (RPRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Royalty Pharma Plc Azioni (RPRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Feb 02 '26 |
Sale |
42.08 |
108,424 |
4,562,905 |
30,167 |
| Coyne Terrance P. | EVP & CFO |
Feb 04 '26 |
Sale |
43.29 |
20,163 |
872,913 |
22,885 |
2.25%
0.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):